Table 10.
Participants Reporting at Least 1 Hospitalization, Adverse Experience, or Condition During Follow-up, by Treatment*
|
No. (%) |
|||
|---|---|---|---|
| No Antioxidants (n = 1798) | Antioxidants (n = 1823) | Total (n = 3621) | |
| Primary hospitalization cause45 | |||
| Infections† | 15 (0.8) | 29 (1.6) | 44 (1.2) |
| Mild/moderate symptoms‡ | 181 (10.1) | 135 (7.4) | 316 (8.7) |
| Primary adverse experience cause45 | |||
| Circulatory† | 15 (0.8) | 6 (0.3) | 21 (0.6) |
| Skin, subcutaneous tissue‡ | 18 (1.0) | 41 (2.2) | 59 (1.6) |
| Follow-up condition§ | |||
| Change in skin color‡ | 108 (6.0) | 151 (8.3) | 259 (7.2) |
| Chest pain† | 415 (23.1) | 368 (20.2) | 783 (21.6) |
|
No. (%) |
|||
|---|---|---|---|
| No Zinc (n = 1838) | Zinc (n = 1783) | Total (n = 3621) | |
| Primary hospitalization cause45 | |||
| Genitourinary‡ | 90 (4.9) | 134 (7.5) | 224 (6.2) |
| Males‡ | 36 (4.4) | 66 (8.6) | 102 (6.4) |
| Females | 54 (5.3) | 68 (6.7) | 122 (6.0) |
| Mild/moderate symptoms† | 143 (7.8) | 173 (9.7) | 316 (8.7) |
| Primary adverse experience cause45 | |||
| Circulatory† | 5 (0.3) | 16 (0.9) | 21 (0.6) |
| Follow-up condition§ | |||
| Anemia‡ | 187 (10.2) | 236 (13.2) | 423 (11.7) |
| Difficulty swallowing pills† | 281 (15.3) | 318 (17.8) | 599 (16.5) |
*
Of nearly 100 comparisons, only causes and conditions significantly different by treatment are presented.
†
P<.05.
‡
P<.01.
§
Self-reported in response to predefined list of signs and symptoms suggesting an adverse event.